CD49d Expression Identifies a Chronic-lymphocytic Leukemia Subset with High Levels of Mobilized Circulating CD34(+) Hemopoietic Progenitors Cells

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Nov 9

PMID 24202404

Citations 4

Authors

F M Rossi

A Zucchetto

E Tissino

M Dal Bo

R Bomben

C Caldana

F Pozzo

G Del Poeta

D Rossi

G Gaidano

V Gattei

Affiliations

Soon will be listed here.

Citing Articles

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond.

Pozzo F, Bittolo T, Tissino E, Zucchetto A, Bomben R, Polcik L Cancers (Basel). 2022; 14(12).

PMID: 35740661 PMC: 9221163. DOI: 10.3390/cancers14122997.

NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells.

Di Ianni M, Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F Front Oncol. 2018; 8:105.

PMID: 29732315 PMC: 5919960. DOI: 10.3389/fonc.2018.00105.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, DAgaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D Oncotarget. 2015; 6(22):19102-17.

PMID: 26036258 PMC: 4662478. DOI: 10.18632/oncotarget.3905.

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?.

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B J Hematol Oncol. 2015; 8:16.

PMID: 25886184 PMC: 4345016. DOI: 10.1186/s13045-015-0113-9.

References

Del Poeta G, Dal Bo M, Del Principe M, Pozzo F, Rossi F, Zucchetto A . Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. Br J Haematol. 2012; 160(3):415-8. DOI: 10.1111/bjh.12128. View

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

Brocklebank A, Sparrow R . Enumeration of CD34+ cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry. 2001; 46(4):254-61. DOI: 10.1002/cyto.1136. View

Bonig H, Priestley G, Oehler V, Papayannopoulou T . Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol. 2007; 35(2):326-34. PMC: 1847625. DOI: 10.1016/j.exphem.2006.09.017. View

Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D . The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia. 2012; 26(6):1301-12. DOI: 10.1038/leu.2011.369. View

Shanafelt T, Geyer S, Bone N, Tschumper R, Witzig T, Nowakowski G . CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008; 140(5):537-46. PMC: 4477272. DOI: 10.1111/j.1365-2141.2007.06965.x. View

Engelhardt B, Kappos L . Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2007; 5(1):16-22. DOI: 10.1159/000109933. View

Vincent A, Cawley J, Burthem J . Integrin function in chronic lymphocytic leukemia. Blood. 1996; 87(11):4780-8. View

Bonig H, Wundes A, Chang K, Lucas S, Papayannopoulou T . Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008; 111(7):3439-41. PMC: 2275012. DOI: 10.1182/blood-2007-09-112052. View

10.

Zohren F, Toutzaris D, Klarner V, Hartung H, Kieseier B, Haas R . The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008; 111(7):3893-5. DOI: 10.1182/blood-2007-10-120329. View

11.

Rigolin G, Fraulini C, Ciccone M, Mauro E, Bugli A, De Angeli C . Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2005; 107(6):2531-5. DOI: 10.1182/blood-2005-04-1768. View

12.

Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R . Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med. 2009; 7:76. PMC: 2747913. DOI: 10.1186/1479-5876-7-76. View

13.

Gattei V, Bulian P, Del Principe M, Zucchetto A, Maurillo L, Buccisano F . Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2007; 111(2):865-73. DOI: 10.1182/blood-2007-05-092486. View

14.

Rigolin G, Maffei R, Rizzotto L, Ciccone M, Sofritti O, Daghia G . Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. Cancer. 2010; 116(8):1926-37. DOI: 10.1002/cncr.24961. View

15.

Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Russo S . Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. J Cell Physiol. 2004; 204(1):113-23. DOI: 10.1002/jcp.20269. View